Trial · NCT02024646

Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

NCT02024646, Phase 3, Completed, Bausch Health Americas, Inc.; results first posted 2020-08-20

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis. Trials, record NCT02024646. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02024646

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
NCT number: NCT02024646
Status: Completed
Phases: Phase 3
Enrollment: 484 participants, actual
Lead sponsor: Bausch Health Americas, Inc.
Conditions: Psoriatic Arthritis
Interventions: 210 mg brodalumab, 140 mg brodalumab, Placebo
First posted: 2013-12-31
Last updated: 2020-08-20
Other registries' IDs: eudract:2013-003553-16
Results first posted: 2020-08-20

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	ACR20 (American College of Rheumatology 20% Improvement) Response Rate Through Week 16	Baseline and 16 Weeks	ACR20 is used as a measurement of the proportion of subjects who are reaching a 20% improvement of tender an swollen joint counts. The higher percent of subjects reaching a higher improvement percentage shows greater success.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	ACR20 (American College of Rheumatology 20% Improvement) Response Rate Through Week 16	Baseline and 16 Weeks	The Primary Analysis Set consists of all randomized subjects who had the opportunity to complete the week 16 visit prior to termination of the study.~The numbers in the outcome measure data table reflect the percentage of subjects achieving ACR20.	Percentage of Participants	NUMBER

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
ACR20 (American College of Rheumatology 20% Improvement) Response Rate Through Week 16	210 mg Brodalumab	41.8	Percentage of Participants
ACR20 (American College of Rheumatology 20% Improvement) Response Rate Through Week 16	140 mg Brodalumab	48.9	Percentage of Participants
ACR20 (American College of Rheumatology 20% Improvement) Response Rate Through Week 16	Placebo	24.7	Percentage of Participants

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	210 mg Brodalumab	163
Overall Study	STARTED	140 mg Brodalumab	160
Overall Study	STARTED	Placebo	161
Overall Study	COMPLETED	210 mg Brodalumab	131
Overall Study	COMPLETED	140 mg Brodalumab	135
Overall Study	COMPLETED	Placebo	133
Overall Study	NOT COMPLETED	210 mg Brodalumab	32
Overall Study	NOT COMPLETED	140 mg Brodalumab	25
Overall Study	NOT COMPLETED	Placebo	28

Source ClinicalTrials.gov

Adverse events126

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Nasopharyngitis	Infections and infestations	210 mg Brodalumab	28	163
other	Nasopharyngitis	Infections and infestations	140 mg Brodalumab	17	160
other	Nasopharyngitis	Infections and infestations	Placebo	7	161
other	Upper Respiratory Tract Infection	Infections and infestations	210 mg Brodalumab	16	163
other	Upper Respiratory Tract Infection	Infections and infestations	140 mg Brodalumab	16	160
other	Upper Respiratory Tract Infection	Infections and infestations	Placebo	2	161
other	Sinusitus	Infections and infestations	210 mg Brodalumab	10	163
other	Sinusitus	Infections and infestations	140 mg Brodalumab	2	160
other	Sinusitus	Infections and infestations	Placebo	2	161
other	Oral Herpes	Infections and infestations	210 mg Brodalumab	6	163

1 to 10 of 126Source ClinicalTrials.gov

See all 126 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	210 mg Brodalumab
Total, all-cause mortality	140 mg Brodalumab
Total, all-cause mortality	Placebo
Total, other adverse events	210 mg Brodalumab	91	163
Total, other adverse events	140 mg Brodalumab	85	160
Total, other adverse events	Placebo	83	161
Total, serious adverse events	210 mg Brodalumab	5	163
Total, serious adverse events	140 mg Brodalumab	3	160
Total, serious adverse events	Placebo	5	161

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02024646

GET https://conductscience.org/api/trials/v1/NCT02024646/events?page=2

API reference For AI assistants